BiotechTube

TKM-100802 for Injection + Placebo

Phase 1Terminated
0 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ebola Virus Infection

Conditions

Ebola Virus Infection

Trial Timeline

Jan 1, 2014 → Jul 1, 2015

NCT ID
NCT02041715

About TKM-100802 for Injection + Placebo

TKM-100802 for Injection + Placebo is a phase 1 stage product being developed by Arbutus Biopharma for Ebola Virus Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT02041715. Target conditions include Ebola Virus Infection.

What happened to similar drugs?

2 of 4 similar drugs in Ebola Virus Infection were approved

Approved (2) Terminated (1) Active (1)
✅rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
🔄V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
✅BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
❌Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3

Hype Score Breakdown

Clinical
6
Activity
0
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02041715Phase 1Terminated

Competing Products

20 competing products in Ebola Virus Infection

See all competitors
ProductCompanyStageHype Score
Ad26.ZEBOV vaccineJohnson & JohnsonPhase 2
35
rVSVΔG-ZEBOV-GP, V920 + Chikenpox or Varicella vaccine (VARILRIX)MerckPhase 1/2
32
V920 VaccineMerckPhase 1
29
Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV∆G-ZEBOV-GP)MerckPhase 2
39
rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)MerckApproved
50
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus VaccineMerckPhase 2
35
V920MerckPhase 1
29
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920MerckPhase 3
40
BioNTech - Pfizer COVID-19 vaccine + 1mL saline solution + rVSV∆G-ZEBOV-GPMerckApproved
50
V920MerckPhase 1
29
GS-5734Gilead SciencesPhase 2
35
REGN3470-3471-3479Regeneron PharmaceuticalsPre-clinical
30
Ervebo + InmazebRegeneron PharmaceuticalsPhase 2
42
AVI-7537United TherapeuticsPhase 1
18
Placebo + AVI-6002United TherapeuticsPhase 1
26
Ad26.ZEBOV + MVA-BN-FiloBavarian NordicPhase 3
29
CMX001Jazz PharmaceuticalsPhase 2
24
BrincidofovirJazz PharmaceuticalsPhase 2
24
cAd3-Marburg + cAd3-EBO-SICON plc.Phase 1
26
Base Dose EBOV GP Vaccine + 2x Base Dose EBOV GP Vaccine + 4x Base Dose EBOV GP Vaccine + 8x Base Dose EBOV GP Vaccine + Placebo + Matrix-M AdjuvantNovavaxPhase 1
23